Roche CEO says only the big will survive in generics. With no clear point of difference over competitors me-too drug makers will go the way of the dinosaur.
ACL are not big. ACL will never be big. Ergo, ACL will not survive. Dr. Reddys and GSK are and will.
Already they have lost first mover advantage to a competitor with others on the way. All of which have very little point of difference.
The only thing that can give ACL holders hope is a takeover bid, full or partial, from Dr. Reddy's and/or GSK.
Makes no difference what Bioshares or anyone else says. I would much rather take my cue from the CEO of Roche thanks.
- Forums
- ASX - By Stock
- TSN
- report - 2 weeks to approval?
report - 2 weeks to approval?, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online